Drugs / INCA33890
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05836324 | Jul 2023 → Jan 2027 expected | cancer, metastatic neoplasm | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07284849 | Mar 2026 → Dec 2028 expected | colorectal cancer | Incyte Corporation | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06179160 Background | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Incyte Corporation | Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 incyte.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCA33890 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06179160 ↗ |